Management of Anthrax | Zendy

John G. Bartlett | Zendy; Thomas V. Inglesby | Zendy; Luciana Borio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management of Anthrax

Author(s) -

John G. Bartlett,

Thomas V. Inglesby,

Luciana Borio

Publication year - 2002

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/341902

Subject(s) - medicine , bacillus anthracis , public health , biological warfare , intensive care medicine , anthrax vaccines , etiology , mandate , pneumonia , antibiotics , environmental health , medical emergency , immunology , pathology , microbiology and biotechnology , immunization , toxicology , dna vaccination , genetics , antigen , bacteria , political science , law , biology

From 3 October 2001 through 16 November 2001, in the United States, there were 18 confirmed cases of inhalational and cutaneous anthrax, an additional 4 suspected cases of cutaneous anthrax, and 5 deaths due to inhalational anthrax. Although the number of cases was relatively small, this experience brought bioterrorism and its potential to sharp focus as thousands of people began receiving prophylactic antibiotics after possible exposure to anthrax spores. These events have resulted in a substantial impact on the health care system, including the rewriting of pneumonia guidelines, new emphasis on identification of microbial etiology, substantial infusion of funds for bioterrorism-related research, and a sudden mandate for regional disaster and public health planning. This article provides clinicians with clinically relevant information about the diagnosis and management of anthrax.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research